Abstract
Evaluation of efficacy of hyaluronic acid preservative-free preparation 0.3 % in the prevention of secondary dry eye syndrome in patients after cataract phacoemulsification
Highlights
In the prevention of secondary dry eye syndrome in patients after cataract phacoemulsification Oleg I
Purpose: to determine the clinical efficacy of a non-preservative drug based on sodium hyaluronate 0.3 % (Gilan) in the correction of secondary dry eye syndrome (DES) manifestations in patients after cataract phacoemulsification (CPE), based on monitoring clinical and functional characteristics of the ocular surface
The main group of patients (31 patients) received, in addition to the standard postoperative treatment, a non-preservative drug based on sodium hyaluronate 0.3 % (Gilan), whilst the control group (31 patients) received standard therapy
Summary
In the prevention of secondary dry eye syndrome in patients after cataract phacoemulsification Oleg I. Purpose: to determine the clinical efficacy of a non-preservative drug based on sodium hyaluronate 0.3 % (Gilan) in the correction of secondary dry eye syndrome (DES) manifestations in patients after cataract phacoemulsification (CPE), based on monitoring clinical and functional characteristics of the ocular surface. В результате у пациентов, перенесших ФЭК, происходит развитие или усиление уже имеющихся симптомов ССГ, что приводит к снижению функционального эффекта операции [19].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
